CTTI Announces Promotion of Morgan Hanger to Executive Director
Today, CTTI proudly announced Morgan Hanger as its next Executive Director.
“CTTI has been at the center of advancing clinical trial transformation through public-private collaboration, and that leadership will continue under Morgan Hanger,” said Dr. Mark McClellan, CTTI Executive Committee Chair, and Founding Director, Duke-Margolis Center for Health Policy. “Combined with Sally Okun’s lasting contributions, a thoughtful transition plan, and a strong team, CTTI is uniquely positioned—at critical time—to identify and support innovative strategies to speed the development of better clinical evidence to help more patients at a lower cost.”
Serving as CTTI’s Director of Strategic Programs since January 2022, Hanger has collaborated on strategic initiatives related to the organization’s Transforming Trials 2030 vision and led the early-stage activities of CTTI’s newest project, Measuring Trials Transformation. Prior to CTTI, she spent three years as an independent consultant advising health technology companies and innovators on the development of new products. Previously, she served as vice president of the online patient research network PatientsLikeMe (PLM), where she led programs utilizing patient-generated health data in life sciences and regulatory settings. Hanger’s earlier work provided consulting and advisory services to leading pharma, biotech companies, and professional societies to create more effective research strategies. She also held positions within the Health Outcomes Group at Memorial Sloan Kettering Cancer Center and the Congressional Budget Office.
“I am excited and honored to lead CTTI at such an exciting moment in its trajectory,” Hanger said. “We have terrific members, partners, and a highly adaptive and talented team, all of whom are eager to drive change across the clinical trials enterprise. We will continue to lean into the transformation part of our directive by deepening our implementation resources, focusing on enterprise-wide measurement, and supporting the FDA as they anticipate and facilitate the evolution of trials with modernized designs, data, and capabilities.”
“I know I speak for the entire CTTI team in celebrating Morgan’s promotion to the Executive Director position,” said Sally Okun, CTTI’s current Executive Director, who is retiring at the end of this year. “Over the past two years, Morgan’s unique combination of innovative thinking, operational skills, and inclusive engagement have guided the development of an impactful and measurable strategic plan. It is a rare privilege to have a person of Morgan’s caliber so well positioned to seamlessly continue advancing CTTI towards its transformational 2030 vision.”
Hanger, who assumes her new role in January 2024, will work closely over the next several months with Okun to ensure a smooth transition. Both Hanger and Okun are working with Executive Committee leadership – Chair Mark McClellan, Duke Co-chair John Alexander, and FDA Co-chair Khair ElZarrad – on a thoughtful succession plan that ensures the highest level of team and organizational integrity. In addition, the CTTI team is actively involved in this transition process – one that considers their voices and reflects their perspectives about the next generation of CTTI leadership and its strategy moving forward.